Abstract Number: 2182 • 2018 ACR/ARHP Annual Meeting
Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data
Background/Purpose: Given alendronate’s (ALN) prolonged skeletal retention and emerging safety concerns, the ASBMR task force recommended consideration of a “drug holiday” after 5 years of…Abstract Number: 2183 • 2018 ACR/ARHP Annual Meeting
Access to Prescription Drugs in Canada: Results from an Online Survey
Background/Purpose: Prescription medications are an important treatment option for patients living with arthritis. However, patients may often not have access to certain medications they hear…Abstract Number: 2184 • 2018 ACR/ARHP Annual Meeting
An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
Background/Purpose: Diagnosis (dx) of systemic lupus erythematosus (SLE) is made via a combination of clinical and laboratory examinations; the sensitivity and specificity (S&S) of standard…Abstract Number: 2185 • 2018 ACR/ARHP Annual Meeting
Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) affects over 1 million Medicare enrollees. Despite the size of this population, costs for RA within Medicare remain poorly understood, especially…Abstract Number: 2186 • 2018 ACR/ARHP Annual Meeting
Process Evaluation of a Culturally-Sensitive, Community Based Self-Management Program for First Nations People with Arthritis and Their Families
Background/Purpose: First Nation community consultations identified arthritis as a priority health concern and the need for culturally sensitive health services adapted to community needs. In…Abstract Number: 2187 • 2018 ACR/ARHP Annual Meeting
Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada
Background/Purpose: The Calgary zone of Alberta Health Services serves a population of almost 2million Canadians over a wide geographical area and is underserved in terms…Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…Abstract Number: 2189 • 2018 ACR/ARHP Annual Meeting
Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort
Background/Purpose: Multiple small studies have demonstrated that patients with rheumatic disease can and are willing to use smartphones to track disease severity. The objective of…Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…Abstract Number: 2191 • 2018 ACR/ARHP Annual Meeting
Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
Background/Purpose: Ultrasound (US)-guided injections in musculoskeletal medicine typically utilize either local puncture site sterility or conventional surgical sterility. We report on the safety and complications…Abstract Number: 2192 • 2018 ACR/ARHP Annual Meeting
User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)
Background/Purpose: Methotrexate (MTX) is the cornerstone for the treatment of RA as monotherapy or in combination. While its cost effectiveness in halting the disease is…Abstract Number: 2193 • 2018 ACR/ARHP Annual Meeting
Online Direct-to-Patient Recruitment for Systemic Lupus Erythematosus Results in Rapid Enrollment
Background/Purpose: For precision medicine to address the dynamic nature of autoimmune diseases, more frequent measurements of disease activity and therapy response are needed. We report…Abstract Number: 2194 • 2018 ACR/ARHP Annual Meeting
Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China
Background/Purpose: Adverse events (AE) during treatment in RA patients are unavoidable. Monitoring AEs in real time during long-term treatment is critical for AE detection and…Abstract Number: 2195 • 2018 ACR/ARHP Annual Meeting
Predictive Factors of a Positive PET/CT Scan for Vascular Involvement in Patients with Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) is often the presenting manifestation of giant cell arteritis (GCA). Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) scan often discloses the presence…Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV). Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…